Celgene Corporation (CELG): Still Revving Up With Revlimid
What a roll Celgene Corporation (NASDAQ:CELG) has been on lately. The company has experienced success after success in recent months.
Bristol Myers Squibb Co (BMY)
Market is closed
News
- First
- << Previous
- 541 - 545
5 Big Winners and Losers From Earnings Season: Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Eli Lilly & Co. (LLY)
Earnings season is a wrap for many of the brightest stars of the health care sector: Big pharma's big disappointments and successes are in the books, and investors are looking ahead to the future.
What Will Type 2 Diabetes Treatments Look Like in 5 Years? Merck & Co., Inc. (MRK), AstraZeneca plc (AZN)
Times are changing in the biotech sector. No longer can companies simply sit on their FDA-approved drugs for years at a time, reaping the benefits from a decade or more of research.
Sanofi SA (SNY)'s New Diabetes Play Moves Forward
Sanofi SA (ADR) (NYSE:SNY) starts the week with a new European Union approval for the type 2 diabetes injectable Lyxumia.
Two Peas in a Pharma Pod: Pfizer Inc (PFE), Bristol Myers Squibb Co. (BMY)
Pfizer's 2012 revenue was down 10%; Bristol-Myers Squibb's was off by 17%. Both are down because of expirations of megablockbusters they used to own.
- First
- << Previous
- 541 - 545
Billionaire Hedge Funds
